Bioaccumulation (PFAS Context)

Bioaccumulation refers to the progressive build-up of PFAS in living organisms over time, where the rate of intake exceeds the rate of elimination. PFAS bioaccumulate due to their extreme chemical stability—the carbon-fluorine bond resists metabolic breakdown. Certain PFAS, particularly long-chain perfluoroalkyl acids like PFOA and PFOS, bind to proteins in blood serum and liver tissue and can have half-lives of several years in the human body. Bioaccumulation is a key criterion in hazard classification under REACH, the Stockholm Convention, and EPA risk assessments.

REACH Regulation (EC) No 1907/2006, Annex XIII (PBT/vPvB criteria); Stockholm Convention on POPs; EPA PFAS Strategic Roadmap (2021, updated 2023).

Bioaccumulation is one of the three PBT (Persistent, Bioaccumulative, Toxic) criteria that trigger the most restrictive regulatory actions for chemicals. When a PFAS is identified as bioaccumulative, it can be classified as a Substance of Very High Concern under REACH, listed under the Stockholm Convention, or subject to enhanced reporting under TSCA. For manufacturers, this means any product containing a bioaccumulative PFAS faces escalating regulatory pressure—from disclosure and reporting obligations today to potential outright bans in the near future.

PFOS has been measured with a half-life of approximately 5.4 years in human blood. This bioaccumulation profile is why PFOS was among the first PFAS listed under the Stockholm Convention (2009) and subsequently restricted under EU POPs Regulation and REACH.